FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2117328200> ?p ?o ?g. }

• W2117328200 endingPage "224" @default.
• W2117328200 startingPage "207" @default.
• W2117328200 abstract "Bisphosphonate drugs are a group of pyrophosphate analogues which bind avidly to hydroxyapatite bone mineral surfaces and their major action is to inhibit osteoclast activity and thus bone resorption. In oncology, their role in metastatic bone disease is well established, but there is increasing interest in their potential role in preventing and treating cancer-induced bone loss and their possible anti-tumour effects. Metastatic bone disease is associated with a variety of skeletal complications, including pathologic fractures, bone pain, impaired mobility, spinal cord compression and hypercalcaemia. Intravenous bisphosphonates, particularly zoledronic acid, in conjunction with rehydration, are now established as the treatment of choice for hypercalcaemia. For treatment of bone pain, it has also been shown that bisphosphonates can be an effective supplementary approach to radiotherapy. In breast cancer and myeloma, bisphosphonates have now become part of standard therapy to treat and prevent skeletal-related events (SRE) and, until recently, treatment was largely with intravenous pamidronate or oral clodronate. However, large, randomised, multicentre trials using intravenous administration of the highly potent bisphosphonate zoledronic acid every 3-4 weeks have recently demonstrated a reduction of 20% in the risk of developing an SRE compared with pamidronate for patients with breast cancer. Moreover, these trials have demonstrated, for the first time, that a bisphosphonate significantly reduces the occurrence of skeletal events in hormone-refractory prostate cancer and in non-small cell lung cancer and a range of other solid tumours. Investigations into the potential of the relatively low potency bisphosphonate, clodronate, for the prevention of bone metastases in breast cancer have produced conflicting data. Further large, randomised studies with clodronate and zoledronic acid are planned and until the results are available it is not possible to identify a definite adjuvant role for bisphosphonates. Evidence is accumulating in vitro that bisphosphonates are also able to directly affect tumour cells, in addition to their effects on osteoclasts, with zoledronic acid being particularly potent. Over recent decades there has been a significant improvement in cure rates and survival times in certain cancers and the use of chemotherapy and hormone therapy has expanded greatly, leading to increasing numbers of long-term survivors who have received these treatments. Management of treatment-induced bone loss is therefore assuming a greater importance and bisphosphonates represent an attractive treatment option in such patients. Several placebo-controlled trials using oral clodronate, oral risedronate, intravenous pamidronate and intravenous zoledronic acid have all now demonstrated benefits in reducing the loss in bone mineral density." @default.
• W2117328200 created "2016-06-24" @default.
• W2117328200 creator A5043962338 @default.
• W2117328200 creator A5051980635 @default.
• W2117328200 creator A5056951639 @default.
• W2117328200 date "2004-06-01" @default.
• W2117328200 modified "2023-10-13" @default.
• W2117328200 title "The role of bisphosphonates in breast and prostate cancers." @default.
• W2117328200 cites W1517801548 @default.
• W2117328200 cites W1521095066 @default.
• W2117328200 cites W1532955823 @default.
• W2117328200 cites W1552949608 @default.
• W2117328200 cites W1584998852 @default.
• W2117328200 cites W1589933893 @default.
• W2117328200 cites W1606563840 @default.
• W2117328200 cites W1761951195 @default.
• W2117328200 cites W1768011742 @default.
• W2117328200 cites W1800396987 @default.
• W2117328200 cites W1842425533 @default.
• W2117328200 cites W1873492158 @default.
• W2117328200 cites W1880057253 @default.
• W2117328200 cites W1906721103 @default.
• W2117328200 cites W1913723147 @default.
• W2117328200 cites W1928668153 @default.
• W2117328200 cites W1938796902 @default.
• W2117328200 cites W1944967894 @default.
• W2117328200 cites W1951349736 @default.
• W2117328200 cites W1967771383 @default.
• W2117328200 cites W1970993628 @default.
• W2117328200 cites W1973015781 @default.
• W2117328200 cites W1974256738 @default.
• W2117328200 cites W1974305754 @default.
• W2117328200 cites W1975441355 @default.
• W2117328200 cites W1978228601 @default.
• W2117328200 cites W1980224053 @default.
• W2117328200 cites W1981874801 @default.
• W2117328200 cites W1982987807 @default.
• W2117328200 cites W1983310397 @default.
• W2117328200 cites W1984261323 @default.
• W2117328200 cites W1989014251 @default.
• W2117328200 cites W1989622431 @default.
• W2117328200 cites W1998924309 @default.
• W2117328200 cites W2001897537 @default.
• W2117328200 cites W2004931703 @default.
• W2117328200 cites W2005383842 @default.
• W2117328200 cites W2006825597 @default.
• W2117328200 cites W2007001439 @default.
• W2117328200 cites W2007510934 @default.
• W2117328200 cites W2010486222 @default.
• W2117328200 cites W2012364920 @default.
• W2117328200 cites W2014223559 @default.
• W2117328200 cites W2017654113 @default.
• W2117328200 cites W2020876435 @default.
• W2117328200 cites W2023227918 @default.
• W2117328200 cites W2026455376 @default.
• W2117328200 cites W2029838719 @default.
• W2117328200 cites W2034437450 @default.
• W2117328200 cites W2036488551 @default.
• W2117328200 cites W2037314712 @default.
• W2117328200 cites W2037542472 @default.
• W2117328200 cites W2040874414 @default.
• W2117328200 cites W2041868422 @default.
• W2117328200 cites W2043017963 @default.
• W2117328200 cites W2048258524 @default.
• W2117328200 cites W2053925700 @default.
• W2117328200 cites W2058500908 @default.
• W2117328200 cites W2059972525 @default.
• W2117328200 cites W2062992747 @default.
• W2117328200 cites W2063048904 @default.
• W2117328200 cites W2065771840 @default.
• W2117328200 cites W2076493089 @default.
• W2117328200 cites W2077304538 @default.
• W2117328200 cites W2082333541 @default.
• W2117328200 cites W2084651782 @default.
• W2117328200 cites W2088834583 @default.
• W2117328200 cites W2093571282 @default.
• W2117328200 cites W2094944364 @default.
• W2117328200 cites W2095170176 @default.
• W2117328200 cites W2097514725 @default.
• W2117328200 cites W2098097319 @default.
• W2117328200 cites W2102482103 @default.
• W2117328200 cites W2103314990 @default.
• W2117328200 cites W2104298626 @default.
• W2117328200 cites W2114358979 @default.
• W2117328200 cites W2114991203 @default.
• W2117328200 cites W2115335453 @default.
• W2117328200 cites W2115871403 @default.
• W2117328200 cites W2122560580 @default.
• W2117328200 cites W2126048792 @default.
• W2117328200 cites W2127677509 @default.
• W2117328200 cites W2130251213 @default.
• W2117328200 cites W2131284079 @default.
• W2117328200 cites W2136257629 @default.
• W2117328200 cites W2137676632 @default.
• W2117328200 cites W2138220544 @default.
• W2117328200 cites W2144860907 @default.
• W2117328200 cites W2159100092 @default.
• W2117328200 cites W2159858973 @default.

• next